A pilot study of pancreatic islet amyloid PET imaging with [18F]FDDNP
- Submitting institution
-
King's College London
- Unit of assessment
- 12 - Engineering
- Output identifier
- 97629730
- Type
- D - Journal article
- DOI
-
10.1097/MNM.0000000000000849
- Title of journal
- Nuclear Medicine Communications
- Article number
- -
- First page
- 659
- Volume
- 39
- Issue
- 7
- ISSN
- 0143-3636
- Open access status
- Compliant
- Month of publication
- June
- Year of publication
- 2018
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
9
- Research group(s)
-
-
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- There is evidence that Type 2 diabetes (T2DM) and Alzheimer's disease (AD) are closely associated with protein misfolding disorders. This study provided strong evidence that an AD PET tracer, [18F]FDDNP, can be used for non-invasive imaging of islet amyloid in T2DM patients. It has the advantage of simultaneously measuring amyloid burden in both central nervous system and peripheral organs, which might reveal the interrelationship of these two age-related diseases at the molecular level. This work led to an ongoing phase II clinical trial [ChiCTR1800017825] aiming to measure the pancreatic islet amyloid burden in T2DM patients with AD symptoms using [18F]FDDNP.
- Author contribution statement
- -
- Non-English
- No
- English abstract
- -